2018 Fiscal Year Final Research Report
Master Regulator of squamous cell carcinoma TSC22D4/THG-1 and its application for medical development
| Project/Area Number |
17K19580
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor biology and related fields
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Suzuki Hiroyuki
Hipolito Christopher John
|
|---|
| Project Period (FY) |
2017-06-30 – 2019-03-31
|
| Keywords | TSC22D4/THG-1 / 扁平上皮がん / NRF2 / HIF1α / β-catenin / SALL4 / 特殊環状ペプチド |
|---|
| Outline of Final Research Achievements |
Transforming Growth Factor β 1-stimulated clone 22 domain family 4 (TSC22D4)/ TSC22 Homologous Gene-1 (THG-1) is highly expressed and commonly involved in squamous cell carcinoma (SCC) as a tissue specific oncogenic molecule. We have examined the molecular mechanism how THG-1 develop SCC. We also obtained THG-1-binding non-standard macrocyclic peptides, which may be applicable for the development of novel SCC therapy in the future.
|
| Free Research Field |
実験病理学、腫瘍学
|
| Academic Significance and Societal Importance of the Research Achievements |
皮膚がん、頭頸部がん、喉頭がん、食道がん、子宮頸がんのほとんどと肺がんのおよそ20%は、扁平上皮がんという共通の組織型を示す予後不良ながんである。また、頭頸部がんや喉頭がんは、手術による患部の摘出により著しくQOLが低下するため、手術に頼らない治療方法の確立が強く望まれている。本研究は、扁平上皮がんの発生に共通に関与する分子機構を明らかにし、これを標的とする治療の開発につながる基礎研究を行なったことで社会的に大きな意義がある。
|
